TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3723262
Drug: WHO recommended
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO recommended glucose ORS (20 g/L of glucose)
Study: 29856344
Drug: Inactivated varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated varicella zoster vaccine (vaccine consistency lot group)
Study: 20013055
Drug: Chlorella supplementation
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella supplementation (6 g daily from 12th-18th week of gestation until delivery)
Study: 10505808
Drug: EDTA solution
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA solution (pH 7.4)
Study: 10505808
Drug: Saturated citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated citric acid solution (pH 1)
Study: 30235286
Drug: HIV-1 multiantigen
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 multiantigen DNA vaccine (HIV-MAG, 3000 μg) co-administered with IL-12 plasmid DNA adjuvant (0, 250, 1000, or 1500 μg) via electroporation.
Study: 22632452
Drug: Canagliflozin 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 50, 100, 200, 300 mg daily or 300 mg twice daily
Study: 22632452
Drug: Placebo/Sitagliptin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/Sitagliptin 100 mg daily
Study: 20562541
Drug: Vibration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration therapy
Study: 18097228
Drug: Current antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current antihypertensive therapy
Study: 17259790
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily GH injection
Study: 17259790
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily GH injections
Study: 12716484
Drug: IFN-beta1b treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-beta1b treatment (16 patients)
Study: 9165428
Drug: Endovenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endovenous phenytoin (PHT) - two infusions (mean dosage of 18 mg/kg; mean time of 1 hr)
Study: 9165428
Drug: Endovenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endovenous phenytoin (PHT) - one infusion
Study: 4091994
Drug: Phenytoin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 0.5 g
Study: 20171422
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (dispersible tablets) of MMF 1.0 g
Study: 20171422
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (capsules) of MMF 1.0 g
Study: 12173198
Drug: 0.15% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ropivacaine plus sufentanil 0.5 microgram ml-1
Study: 339846
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied caffeine 30%-hydrocortisone 0.5% in hydrophilic ointment
Study: 339846
Drug: Hydrocortisone 0.5%
Normalized name: HYDROCORTISONE 0.5% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 0.5% in hydrophilic ointment
Study: 9794948
Drug: Late surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late surfactant treatment
Study: 6142208
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no surfactant treatment)
Study: 28697127
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg orally 1 hour before ERCP
Study: 28697127
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion only (control group)
Study: 22175055
Drug: PSMC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMC + 300 mL of magnesium citrate (M)
Study: 18710606
Drug: EGCG (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (400 mg capsules, twice daily for 8 weeks)
Study: 18710606
Drug: Placebo (lactose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose, twice daily for 8 weeks)
Study: 16359745
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg alcohol (2 drink equivalent)
Study: 6395526
Drug: Bencyclan (2x
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencyclan (2x 200 mg daily for 8 weeks)
Study: 20568656
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort extract WS 5570 (600-1800 mg/day)
Study: 15580433
Drug: Maxout implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxout implant
Study: 15580433
Drug: Maxout implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxout implant (intraoral placement)
Study: 15580433
Drug: Maxout implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxout implant (transnasal replacement)
Study: 10476242
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of interferon beta-1a administered once weekly
Study: 894798
Drug: Massive penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Massive penicillin dosage (60 million units)
Study: 894798
Drug: Ticarcillin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin (200 mg. per kg.)
Study: 31150976
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group with PFOA concentration > median (4.9 ng/mL)
Study: 17267928
Drug: Internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioural therapy with telephone support
Study: 2109473
Drug: Flumazenil 1
Normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 1 mg
Study: 9135873
Drug: HIV protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV protease inhibitor saquinavir (SQV) in combination with zidovudine (ZDV)
Study: 7520906
Drug: Risperidone (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6, 10, 16 mg/day)
Study: 11530275
Drug: Haloperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10 mg/day)
Study: 11453313
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol
Study: 1092411
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin calcium 5000 IU every eight hours for six days
Study: 31387868
Drug: Pivotal Response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pivotal Response Treatment Package (PRT‐P)
Study: 25031380
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy
Study: 23332882
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin 5mg once daily
Study: 22150035
Drug: Isoniazid-only group
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid-only group (isoniazid 300 mg for 9 months)
Study: 22184370
Drug: AMG 386
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 10 mg/kg QW plus paclitaxel
Study: 22184370
Drug: AMG 386
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 3 mg/kg QW plus paclitaxel
Study: 12458361
Drug: Al-adjuvanted low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Al-adjuvanted low-dose formulations (1.9 micro g HA/strain per dose)
Study: 12458361
Drug: Al-adjuvanted low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Al-adjuvanted low-dose formulations
Study: 12458361
Drug: Standard split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard split virus vaccine (Fluarix)
Study: 12458361
Drug: Al-adjuvanted whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-adjuvanted whole virus formulations with reduced antigen content
Study: 12458361
Drug: Al-adjuvanted whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-adjuvanted whole virus vaccines with low HA content
Study: 9593249
Drug: Mechanical plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical plus oral metronidazole (n = 20)
Study: 9593249
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol preparation (n = 21)
Study: 26445139
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo
Study: 2242972
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg b.i.d., intramuscular injection, starting one day before surgery and continuing for seven postoperative days)
Study: 2242972
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (5000 IU t.i.d., subcutaneous injection, starting two hours before surgery and continuing for seven days)
Study: 8027144
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin
Study: 22268852
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg/day plus Clopidogrel 75 mg/day
Study: 7664901
Drug: Pre-operative radiation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative radiation therapy alone (R)
Study: 2701039
Drug: Propranolol 120‐480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 120‐480 mg daily, mean dose 280 mg for 6‐9 weeks
Study: 2701039
Drug: Pindolol 10‐35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 10‐35 mg daily, mean dose 22 mg for 6‐9 weeks
Study: 67468
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of 200 units of antitetanus serum (A.T.S.) (horse)
Study: 21503000
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg once daily (933 subjects)
Study: 12815302
Drug: Selective endothelin
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective endothelin receptor-A antagonist BQ-123 administered by the intracoronary route
Study: 6756632
Drug: Cefotaxime perioperatively
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime perioperatively plus postoperative doses every six hours for 24 hours
Study: 6756632
Drug: Cefazolin perioperatively
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin perioperatively plus postoperative doses every six hours for 24 hours
Study: 31383609
Drug: Silver nanoparticle
Normalized name: Silver nanoparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver nanoparticle gel (SG)
Study: 28515079
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) 1,000 mg/6 h for 24 h before and immediately following RE
Study: 19149344
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered oxymetazoline
Study: 19149344
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered pseudoephedrine
Study: 9596418
Drug: Intravenous boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous boluses of isosorbide dinitrate
Study: 9596418
Drug: Sublingual sprays
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual sprays of isosorbide dinitrate
Study: 20642206
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mometasone furoate nasal spray (200 microg)
Study: 18560141
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (eye open)
Study: 18560141
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (eye closed)
Study: 18560141
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (patient 2)
Study: 16369892
Drug: HRT (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (conjugated estrogen at a dose of 0.31 mg/day + medroxyprogesterone acetate 2.5 mg/day)
Study: 2179362
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose quinidine-mexiletine combination therapy
Study: 6805621
Drug: Slow-release hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release hydralazine 200 mg once daily
Study: 29379943
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of mixed tocotrienols twice daily for 12 months
Study: 19167122
Drug: Short-term chemotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term chemotherapy (cisplatin 70 mg/m² for 1 day and 5FU 700 mg/m² for 5 days) with radiotherapy (RT) of 60Gy/30 fractions/7 weeks.
Study: 19167122
Drug: Protracted chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted chemotherapy (cisplatin 7 mg/m² for 10 days and 5FU 250 mg/m² for 14 days) with radiotherapy (RT) of 60Gy/30 fractions/7 weeks.
Study: 9625122
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/day
Study: 15688191
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (sCT) 200 IU/day
Study: 10919021
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy with ligation (EISL)
Study: 19626475
Drug: Gadopentetate dimeglumine
Normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadopentetate dimeglumine (0.2 ml/kg)
Study: 2120987
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline, 0.2 ml/kg)
Study: 917259
Drug: Intravenous heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heroin administration
Study: 9314855
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo administration
Study: 19356306
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of docosahexaenoic acid (DHA)
Study: 12486792
Drug: Fluconazole at
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole at 100-400 mg daily for the first 1-3 months post-liver transplantation
Study: 12486792
Drug: Inhaled liposomal
Normalized name: amikacin liposomal Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled liposomal preparations post-organ transplantation or preemptive use of itraconazole
Study: 12486792
Drug: Molecular diagnostic
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular diagnostic techniques for identification and preemptive therapy
Study: 16875470
Drug: Contractubex gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contractubex gel
Study: 2193980
Drug: Aspirin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1 g per day)
Study: 24668638
Drug: Ropivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (20 mg)
Study: 24668638
Drug: Dicaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicaine (20 mg)
Study: 19436994
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (n=15)
Study: 19436994
Drug: High-dose ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ketamine (n=16)
Study: 9683310
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg; vitamin E, 30 mg; beta-carotene, 6 mg) and minerals (selenium, 100 microg; zinc, 20 mg)
Study: 3068098
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g as a single dose
Study: 29088579
Drug: FX006 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX006 32 mg
Study: 27049269
Drug: Fentanyl (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.5 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Study: 27049269
Drug: Remifentanil (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.25 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Study: 21296333
Drug: Dronedarone 400
Normalized name: dronedarone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 400 mg b.i.d.
Study: 8943972
Drug: Antroduodenal manometry
Normalized name: ALCOHOL 80 mL in 100 mL INTRADUODENAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antroduodenal manometry in parenteral-nutrition-dependent children
Study: 8458317
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral vitamin K1 supplement (average 88 micrograms)
Study: 2429279
Drug: Placebo infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions and tablets given at the same schedule as SPG
Study: 25933493
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of α-linolenic acid (ALA) for 60 days
Study: 23042976
Drug: Peginterferon therapy
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon therapy
Study: 21554881
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of arginine vasopressin (AVP) during tasks without social evaluative threat.
Study: 11970745
Drug: Exemestane (EXE)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane (EXE) 25 mg/day
Study: 7673540
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (BT)
Study: 7673540
Drug: Combined dermatological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dermatological educational program and cognitive-behavioral treatment (DEBT)
Study: 19261275
Drug: Sequential timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential timed natural intercourse
Study: 16709314
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 g/day subcutaneously)
Study: 16602632
Drug: Fluvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin treatment
Study: 3364074
Drug: Reaferon (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reaferon (all doses)
Study: 24002145
Drug: Stabilized hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stabilized hyaluronic acid-based gel (Restylane® Vital Light) administered via micropuncture injector
Study: 17011942
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus pravastatin (10-20 mg daily)
Study: 12590005
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus Kava-Kava 200 mg/day
Study: 10813713
Drug: GM-CSF administered
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF administered at a dose of 5 microg/kg/day at 10 p.m.
Study: 8623944
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg added to 180 mg propofol
Study: 1449302
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of metoprolol (control group)
Study: 26166140
Drug: Celecoxib (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200mg daily)
Study: 26166140
Drug: Loxoprofen (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxoprofen (180 mg daily) plus Lansoprazole (15mg daily)
Study: 15545669
Drug: Sequential radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiotherapy (SEQ RT)
Study: 11932900
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CT and Tc-MIBI SPECT
Study: 1090416
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg lorazepam intravenously
Study: 24097843
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg twice daily)
Study: 30732618
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocol (2 μg/kg)
Study: 19376306
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel therapy (additional loading dose followed by 150 mg daily for 6 months)
Study: 19376306
Drug: Standard maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard maintenance clopidogrel therapy (75 mg daily for 6 months)
Study: 11292151
Drug: Virosome subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome subunit vaccine (v-SUV)
Study: 7029236
Drug: Whole virus
Normalized name: rabies, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole virus vaccine (WVV)
Study: 9389880
Drug: Polyunsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated fatty acids (PUFA) in the form of capsules and margarine
Study: 2412042
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg b.i.d.)
Study: 29099926
Drug: Prepubertal Class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepubertal Class II treatment with removable functional appliances